Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Birdie Biopharmaceuticals Inc.
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has been developing immunotherapy products, with their lead product in Phase I clinical trials in the U.S., including a clinical collaboration combination trial with Roche's Tecentriq (atezolizumab), a monoclonal antibody against PD-L1, for treating solid tumors[4][6].
- Therapeutic areas
- Oncology
- Modalities
- ImmunotherapyTLR7/8 agonists
- Industry
- Biotech
02
Partnerships
TLC (Taiwan Liposome Company)Roche (clinical collaboration for combination trial with Tecentriq)
Beyond the preview
Go deeper on Birdie Biopharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Birdie Biopharmaceuticals Inc..